Real-time breath metabolomics to assess early response to CFTR modulators

in adults with cystic fibrosis: an open-label proof-of-concept study

Running title: Real-time breath analysis for CF therapy

Emmanuelle Bardin,[1,2,3,4] Hélène Salvator,[3,5,6] Camille Roquencourt,[2,3] Elodie Lamy,[2] Nicolas

Hunzinger,[2] Isabelle Sermet-Gaudelus,[1,4] Sandra De Miranda,[6] Dominique Grenet,[6] Philippe

Devillier,[3,5] Stanislas Grassin-Delyle[2,3]

[1]Université Paris Cité, INSERM U1151, CNRS UMR8253, Institut Necker Enfants Malades,

Paris, France ; [2]Université Paris-Saclay, UVSQ, INSERM, Infection et inflammation (2I),

U1173, Département de Biotechnologie de la Santé, Montigny le Bretonneux, France ; [3]Hôpital

Foch, Exhalomics®, Suresnes, France ; [4]Hôpital Necker Enfants Malades, Centre de Référence

Maladies Rares, Paris, France ; [5]Université Paris-Saclay, UVSQ, UFR Simone Veil-Santé, VIM-

Suresnes, UMR0892, Suresnes, France ; [6]Hôpital Foch, Service de pneumologie, CRCM -

Centre de Transplantation Pulmonaire, Suresnes, France.

Corresponding author: Stanislas Grassin-Delyle; Exhalomics, Hôpital Foch; 40, rue Worth;

92150 Suresnes; France; E-mail address: s.grassindelyle@hopital-foch.com; Phone:

+33.1.46.25.73.93.

ABSTRACT

Background: The combination of CFTR modulators ivacaftor/tezacaftor/elexacaftor (ETI) achieves unprecedented improvements in clinical symptoms and respiratory function of people with cystic fibrosis. Yet, evaluation is difficult in people with high baseline lung function and the sweat test may vary depending on the type of CFTR mutation. Exhaled breath is a non-invasive sample, rich in personalised metabolic information and breathomics has emerged as a promising tool to monitor and assess therapeutic response. We hypothesised that ETI induces alterations in the breath composition and that these changes may correlate with clinical readouts. **Methods:** Ten adults initiating ETI were enrolled in a prospective open-label study. Exhaled breath was analysed before, after one week and one month of treatment by real-time, proton transfer reaction-mass spectrometry. Clinical symptoms, lung function and sweat test results were recorded. **Results:** A total of 29 breath samples were analysed; 108 volatile organic compounds (VOCs) were consistently detected. In responders (8/10), 21 VOCs were significantly modified, mostly hydrocarbons or small carbonyl compounds. At baseline, these VOCs exhibited significantly different concentrations compared to healthy young adults; throughout the first month of treatment, their level in CF breath evolved towards that of healthy volunteers. Eight of these also correlated with variations in lung function. **Conclusion:** Real-time breath analysis identified alterations in the breath at the early stages of treatment that tended to normalise after one month. These changes exhibited correlations with clinical indicators, suggesting that breath VOCs may serve as early biomarkers useful for treatment monitoring.

Trial registration: NCT05295524

Keywords: Breathomics; cystic fibrosis; CFTR modulators; real-time mass spectrometry; volatile organic compounds

Key messages:

What is already known on this topic

As efficient new generations of treatments are emerging for patients with CF, we are lacking

early, non-invasive, personalised biomarkers associated with response to therapies. The previous

generation of CFTR modulators modified the composition of breath within 3 months, yet nothing

was known about the early impact of the newer combinations.

What this study adds

The triple combination of CFTR modulators modifies the composition of breath in people with

CF as soon as within one week of treatment and tends to normalise basal alterations in CF

breath. These changes in breath composition may be captured with real-time mass spectrometry

and correlate with clinical outcomes.

How this study might affect research, practice or policy

Real-time breath analysis may become useful in monitoring companion biomarkers associated

with therapeutic response in patients with CF. Identification of related biological pathways could

also help to elucidate the mode of action of these drugs.

BACKGROUND

The development of cystic fibrosis transmembrane conductance regulator (CFTR) modulators is transforming the therapeutic landscape for patients with cystic fibrosis (CF). The combination of the potentiator ivacaftor with the two correctors tezacaftor and elexacaftor (ETI) achieves unprecedented improvements in lung function and quality of life in eligible patients within a few weeks [1]. Correctors support the intra-cellular processing of misfolded CFTR protein resulting from class II mutations such as p.Phe508Del (F508del thereafter) whilst the potentiator improves the functioning of CFTR channels positioned at the apical side of epithelial cells. In pulmonary cells, the restoration of CFTR activity reinstates the ionic osmotic balance which translates into rehydration of lung-lining fluids and restoration of mucociliary clearance [2]. In Europe, ETI is currently approved for patients with at least one F508del mutation but should soon be extended to 177 rare variants already approved in the US by the Food and Drug Administration (FDA) based on an *in vitro* improvement of 10% recovery of CFTR function in Fisher rat thyroid (FRT) cells [3]. In the meantime, regulatory agencies in other countries such as France have allowed temporary compassionate access to ETI to all CF patients not carrying F508del, aged 12 years and older and with advanced CF lung disease, in order to assess possible benefits of the treatment.

Since respiratory status still mostly determines prognosis, clinical evaluation of people with CF mainly focuses on respiratory function through the monitoring the forced expiratory volume in one second (FEV_1) and forced vital capacity (FVC). However, these endpoints may fail to detect clinical benefit or biological changes in certain cases, for example in people with high baseline lung function and in young children unable to perform lung function tests or, conversely, in people with advanced lung damage [4,5]. Whilst improvement in FEV_1 may be limited in some patients, they are yet likely to experience less exacerbations and to decrease their bacterial load [6] – although long-term studies are still missing on the newest combinations of CFTR

modulators –, to normalise their inflammatory status [7] or to improve their nutritional status [8].

Furthermore, there is a growing proportion of patients who have difficulties to expectorate

sputum which jeopardizes the detection of pulmonary infections. The measurement of sweat

chloride concentration (SCC) often serves as a secondary endpoint in clinical trials as a marker

of CFTR activity, yet it does not always correlate with clinical improvement, e.g. in respiratory

function and symptoms [9,10]. Therefore, there is a rationale to develop alternative tools to

evaluate the effects of novel therapies such as CFTR modulators in patients with a wide range of

mutation severity.

Over the last 50 years, breathomics extended to various areas of respiratory medicine and

emerged as a promising innovative technique. Exhaled breath is a unique biological signature of

the individual, rich in personalised information, reflecting subtle changes in the metabolism, and

can be obtained non-invasively [11]. Exhaled metabolites, known as volatile organic compounds

(VOCs), are thought to result from inflammatory processes, oxidation, or enzymatic reactions,

which may be triggered by drugs. They have been linked to pathologies, infection, ageing,

environmental exposure or therapeutic interventions [12]. A previous study following up 20

F508del-homozygous patients initiating the CFTR modulator dual therapy lumacaftor/ivacaftor

reported significant metabolic changes in exhaled breath profiles after three months which

persisted at 12 months [13]. Online proton-transfer reaction – mass spectrometry (PTR-MS) is a

high-sensitivity, point-of-care technology allowing real-time monitoring of VOCs which has

already demonstrated potential for the diagnosis of infectious or cancerous diseases [14–18].

We hypothesised that ETI-induced in-depth lung metabolic modifications could be observed in

exhaled breath using real-time PTR-MS and that changes in the volatilomic profiles may be

associated with clinical and biological readouts.

METHODS

Study design

We conducted a prospective open-label study at the Foch university hospital (Suresnes, France), enrolling any adult patients with CF (18 years and over) initiating ETI. Patients were participating to the PHEAL-KAFTRIO study, which was approved by an ethics committee (Comité de protection des personnes Sud-Est I, 2021-A03119-32, NCT05295524). All patients provided written informed consent. The study included three visits following up on ETI initiation: before (V1), during the first week (V2) and after one month (V3) of treatment. At each visit, clinical readouts including respiratory functional symptoms (cough, sputum production, dyspnea) and any episodes of exacerbation were recorded. Spirometry outcomes (FEV_1 and FVC in absolute and percentage of predictive values (pp)) were measured according to American Thoracic Society /European Respiratory Society guidelines [19]. Sweat collection was performed using a Macroduct$^{®}$ Sweat Collection System according to the recommendations of the European Cystic Fibrosis Society Clinical Trial Network [20]. Response to ETI was defined by functional criteria, namely an increase of 10% $ppFEV_1$ and/or a drop of more than 20 mmol/L in SCC at V3; patients accessing ETI through the compassionate programme were evaluated after two months by an adjudication committee, who decided whether or not to continue the treatment [9].

Breath analysis

At each visit, volatile metabolites in exhaled breath were analysed with real-time mass spectrometry, using a proton-transfer reaction – quadrupole – time-of-flight mass spectrometer (PTR-Qi-TOF MS; Ionicon, Innsbruck, Austria). Patients blew directly into the instrument via a single-use mouthpiece connected to a thermostatically controlled BET-med device, conveying exhaled VOCs into the instrument. The entire procedure is quick (<5min) with minimal requirement of patient cooperation. This method allows the untargeted detection of VOCs

according to their mass/charge ratio (m/z) in the range 15-500 m/z. Instrument settings and data

processing methodology were the same as previously reported [15,21].

Statistical analysis

Longitudinal univariate analyses were performed using a Fischer test and a linear mixed-effect

model adjusted for multiple testing thanks to the false discovery rate correction (5% risk). VOC

concentrations were compared to those measured with the same method in a separate cohort of

healthy young adults (VOC-COMPARE study, NCT06020521). Correlations were assessed

through a Pearson correlation test to compare the evolution of VOCs and clinical readouts

between timepoints. Multivariate, supervised partial least square – discriminant analysis (PLS-

DA) was carried out on the Metaboanalyst platform (v6.0) [22] on filtered data (the 5% of

variables with the lowest interquartile range were excluded), after log transformation and

autoscaling.

RESULTS

Study population and clinical response

Ten participants (two females) initiating ETI, median age 34 years (interquartile range (IQR)

17), were enrolled in the study from March to December 2022; three patients had compassionate

access and two switched from monotherapy ivacaftor (Table 1). One patient had known chronic

hepatopathy complicated with portal hypertension and was prescribed a reduced ETI daily dose.

At baseline, lung disease stage was variable; all patients were infected with at least one

respiratory pathogen (*Pseudomonas aeruginosa* (5/10), *Staphylococcus aureus* (5/10)). Seven

had daily anti infectious prophylaxis (both inhaled and oral route) throughout the study (Table

S1). Over the course of the study, three patients experienced a mild bronchial exacerbation; two

of them were related to a coronavirus disease (COVID-19) infection and required additional

antibiotics (Table S1).

At V3, six patients carrying F508del experienced clinical improvement and met clinical response

criteria (Table 1). One patient, who was switching from ivacaftor, chose to stop ETI after one

month because of insomnia and the absence of significant respiratory improvement despite a

+8% gain in ppFEV$_1$; his response was deemed inconclusive. Three patients were granted off-

label access to ETI. Based on clinical outcomes at two months' treatment, the adjudication

committee agreed on a lack of response in one patient who discontinued the treatment, one

patient showed an early response, and a third patient showed a delayed response with a +10%

increase in ppFEV1 after two months. Even though response criteria were not met yet at V3 for

this patient, we chose to classify him in the responder group, resulting in a total number of 8/10

responders. Side effects were limited to rash (3/10) and insomnia (1/10). Microbiological

cultures in patients able to cough up sputum (8/10) were comparable to that collected at baseline.

Breath analysis

Detection of volatile organic compounds

A total of 29 breath samples were available from the 10 participants and 108 VOCs were

consistently detected. Unsupervised multivariate analysis revealed a homogeneous dataset with

no obvious confounding factor, the prevailing source of variability being donors (see principal

component analysis plot in Figure S1). Of note, the patient with hepatopathy showed a

distinctive profile at every visit compared to the other patients (Figure S1), with some

particularly intense VOC signals (see heatmap in Figure S2). Overall, PLS-DA showed a

progressive shift of the overall breath profile in responder patients according to visit (Figure 1).

Changes in breath profiles after ETI initiation

Longitudinal analysis identified 21 VOCs significantly modified (*p*-value F-test mixed model

<0.05) in all responder patients upon ETI initiation (Table 2, Figure 2). Amongst the 21 modified

features, 20 were detected in an independent cohort of young adults and 16 VOCs exhibited

different levels in CF patients at baseline compared to healthy volunteers (*p* <0.05) (Figure 2 and

Figure S3). Changes in the breath of CF patients were observed within the first days of treatment

and progressed gradually throughout the first month towards the level measured in healthy

volunteers. After one month, 13 VOCs were still differently expressed in CF patients, yet the gap

and significance had decreased (Figures 2 and S3).

Annotation of VOC biomarkers

The identification of most features of interest was supported by matching PTR-MS data with

data obtained from comprehensive thermal desorption – two-dimensional gas chromatography

coupled to time-of-flight mass spectrometry (TD-GCxGC-TOF-MS) analysis on breath samples

collected from healthy volunteers (VOC-COMPARE, NCT06020521) and from children with

CF (BIO-CFTR, NCT02965326). Propyne (*m/z* 41.039) and dimethylformamide (*m/z* 74.063)

were amongst the most significant VOCs (*p* <0.01) (Figure 2); most of other VOCs were

identified as unsaturated hydrocarbons or small carbonyl compounds (Table 2).

Correlations with clinical outcomes

Correlations between the evolution of VOC concentrations on one the hand, and the evolution of

ppFEV$_1$, ppFVC or SCC on the other hand, were determined. A total of 32 VOCs were

significantly associated with the evolution of one or more clinical readouts between V1 and V2

(Table 2). Variations of four and 13 VOCs robustly correlated at both timepoints (V2-V1 and

V3-V1) with ppFEV$_1$ and ppFVC, respectively (statistically significant correlation range

|r²|=0.66-0.89). Eight of these were significantly modified upon treatment in responders

including VOCs tentatively identified as acetic acid, methylbutene, dimethylformamide,

methylpentene, methylsulfanylpropene and methylpropanoic acid (see examples in Figure 2).

The number of SCC measurements at V3 was insufficient to reach statistical significance but

there were four VOCs significantly associated with SCC variations between V1 and V2, two of

these also correlated with variations in $ppFEV_1$.

DISCUSSION

This is the first study showing that ETI quickly impacts the breath composition and may

contribute to normalise the level of abnormal VOCs in adults with CF. Disease-specific and lung

pathogen-related breath signatures were previously reported in CF patients [23–29] but the

effects of disease-modifying CFTR modulators have been little explored. Neerincx *et al.*

previously reported changes in the concentration of 51 breath VOCs after three months'

lumacaftor/ivacaftor therapy using breath sampling and off-site gas chromatography – mass

spectrometry (GC-MS) analysis [13]. Here, we integrate early temporal information to explore

the response to ETI therapy, which has replaced previous combinations in most patients, using

direct, real-time mass spectrometry. The breath metabolome was quickly and significantly

modified throughout the first month, possibly indicating progressive drug-induced biological

changes. In addition, VOCs modified by ETI tended to return to levels measured in the healthy

population, supporting their relevance as biomarkers of the treatment's action. A few VOCs

normalised after one month mirroring a short-term impact of the treatment, whilst others

progressed more slowly possibly indicating a delayed effect.

Furthermore, the evolution of several breath VOCs correlated with clinical outcomes which

builds upon recent findings by Woollam *et al.* Using GC-MS, they identified a set of VOCs

correlating with ppFEV1 in CF patients experiencing pulmonary exacerbations [30]. In our

study, eight VOCs significantly modified upon treatment were also consistently (at both V2 and

V3) associated with variations in lung function (ppFEV1 or ppFVC). Modifications within the

lung environment such as mucus clearance, shifts in the microbiome, regulation of inflammation

and oxidative stress, or restructuring of cell membranes can directly both influence lung

mechanical function and alter breath composition. As reported in previous clinical studies [9,31],

some patients experience a delayed response or a limited effect on lung function or SCC making

it delicate to assess the drug efficacy and emphasising the need for complementary early

biomarkers.

Additionally, dysfunctions in other organs are also likely to modulate the breath profile. Aligning

with prior research on liver diseases [32], the patient with hepatopathy in the present study

manifested a characteristic breath signature.

In our responder cohort, 21 VOCs were systematically modified following ETI initiation. ETI's

impact on cellular metabolism is not fully elucidated yet, and identification of such metabolites

may contribute to a better understanding of its mode of action. Propenal (p=0.03) – also known

as acrolein – , acetic acid (p=0.021) and methylpropanoic acid (p=0.048) were decreased. These

belong to the large range of carbonyl compounds that can be generated through lipid

peroxidation, and which have been repeatedly associated with oxidative stress [33]. Woollam *et*

al. also observed a downregulation of longer aldehydes (octanal and nonanal) in patients treated

with CFTR modulators [30]. Another significant VOC, dimethylformamide has been recently

associated with dysfunctions in mitochondria [34] and glucose metabolism [35]. Given ETI is

suspected to affect mitochondrial function [36], a decrease in dimethylformamide (p=0.005)

towards the healthy level may parallel a shift, or even a normalisation, in energy metabolism

upon ETI treatment. Finally, saturated hydrocarbons, commonly reported in breath [12], are

poorly detected by PTR-MS due to their weak affinity for protons [37]. Nevertheless, several

short chain alkens were detected: butene and methylpentene were increased whilst propadiene,

pentadiene and methylbutene were decreased. Decarboxylation of lipids may generate such

byproducts [38] which also points toward a shift in energy metabolism.

Our study has strengths and limitations. First, the PTR-MS technology enables a rapid, point-of-

care, non-invasive analysis of breath. It requires minimal patient cooperation and time, in

contrast to other explorations (spirometry, sweat test…) including breath sampling on desorption

tubes for offline analysis. Compared to GC-MS, the traditional gold standard for breath analysis,

PTR-MS offers complementary advantages in terms of time efficiency and clinical applicability.

By enabling real-time, accurate VOC quantification, PTR-MS eliminates the need for sample

collection, transportation, storage and preparation thereby reducing the likelihood of bias,

degradation and contamination. It has rapid turn-around time, requirement for consumables is

low and does not require qualified personnel. On the other hand, chromatographic separation and

electronic impact ionisation make GC-MS a powerful method for sensitive detection and

identification of VOCs based on their fragmentation patterns. The main limitations of this proof-

of-concept study are related to the limited sample size and to some heterogeneity amongst

participants. This is due to the fact that the other adult patients from our CF centre were already

on ETI at the start of the study thereby preventing comparisons before and after treatment

initiation, and because our high-end, point-of-care real time PTR-MS instrument enables direct

analysis in a single centre only. Furthermore, data collected after a longer treatment period were

not generated. These would help to determine whether the modifications reported here are

enduring (as observed in the lumacaftor/ivacaftor study by Neerincx et *al.* [13]) and the extent to

which ETI may normalise breath profiles. Nevertheless, the objectives of the present study were

to characterise short-term changes in breath composition after treatment initiation and this cohort

illustrates the variety of possible response profiles, including patients with off-label mutations or

switching from other CFTR modulator therapies.

Since the majority of patients with CF are already on ETI in Western countries, future validation

studies should target other drugs and/or populations. In this perspective, real-time breath analysis

could become a quick and non-invasive means for monitoring the exposure to CFTR modulators

and bring novel insights into the pathobiology of CF. This approach may also be extended to the

clinical evaluation of new drug candidates for CF or of CFTR modulators in non-CF respiratory

disorders, such as chronic obstructive pulmonary disease (COPD), asthma and non-CF

bronchiectasis [39–41].

CONCLUSIONS

The recent advent of CFTR modulators on the market has brought unprecedented clinical

improvements and hopes, but also poorly anticipated challenges, including both short- and long-

term monitoring, especially as current tools have limitations for patients with less advanced

disease. Real-time breath analysis may provide a quick and non-invasive alternative to monitor

exposure to CFTR modulators and respiratory improvements, and could bring novel insight into

physiological impact.

LIST OF ABBREVIATIONS

CF: cystic fibrosis

CFTR: cystic fibrosis transmembrane conductance regulator

COPD: chronic obstructive pulmonary disease

COVID-19: coronavirus disease

ETI: elexacaftor, tezacaftor, ivacaftor combination

FDA: food and drug administration

FEV_1: forced expiratory volume in one second

FRT: fisher rat thyroid

FVC: forced vital capacity

GC-MS: gas chromatography – mass spectrometry

IQR: interquartile range

m/z: mass/charge ratio

PLS-DA: partial least square – discriminant analysis

pp: percentage of predictive values

PTR-MS: proton-transfer reaction – mass spectrometry

PTR-Qi-TOF MS: proton-transfer reaction – quadrupole – time-of-flight mass spectrometer

SCC: sweat chloride concentration

TD-GCxGC-TOF-MS: thermal desorption – two-dimensional gas chromatography – time-of-

flight mass spectrometry

VOC(s): volatile organic compound(s)

DECLARATIONS

Ethics approval and consent to participate

Patients were participating to the PHEAL-KAFTRIO study, which was approved by an ethics

committee (Comité de protection des personnes Sud-Est I, 2021-A03119-32, NCT05295524).

All patients provided written informed consent.

Consent for publication

Not applicable

Availability of data and materials

All data generated or analysed during this study are included in this published article and its

supplementary information files.

Competing interests

ISG reports a Vertex Innovation Award, consulting fees and travel support from Vertex therapeutics. The other authors declare that they have no competing interests.

Funding

This work was supported by Région Île de France (VolatolHom, SESAME 2016 and MeLoMane, DIM 1HEALTH 2019), Fondation Foch, ECFS, CF Europe and Vaincre la Mucoviscidose (RC20220503003).

Authors' contributions

EB, HS, DG, SGD designed the study; SDM, DG were site investigators; CR, HS analysed the data; EB, HS, DG, SGD interpreted the data; EB, HS, SGD drafted the manuscript; ISG, PD revised the manuscript; all authors read and approved the final manuscript.

Acknowledgments

The authors wish to acknowledge Thao Nguyen Khoa (Cochin hospital, Paris) for SCC analyses; Antoine Bertrand, Pheal company, for assistance in clinical trial promotion; Bedra Bessaidi, Beatrice d'Urso and Flavie Barret for technical investigation work.

REFERENCES

1   Middleton PG, Mall MA, Dřevínek P, *et al.* Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele. *N Engl J Med.* 2019;381:1809–19. doi: 10.1056/NEJMoa1908639

2 Allen L, Allen L, Carr SB, *et al.* Future therapies for cystic fibrosis. *Nat Commun.*

2023;14:693. doi: 10.1038/s41467-023-36244-2

3 Costa E, Girotti S, Pauro F, *et al.* The impact of FDA and EMA regulatory decision-making

process on the access to CFTR modulators for the treatment of cystic fibrosis. *Orphanet J*

Rare Dis. 2022;17:188.

4 Aalbers BL, Mohamed Hoesein FAA, Hofland RW, *et al.* Radiological and long-term

clinical response to elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with

advanced lung disease. *Pediatric Pulmonology.* 2023;58:2317–22.

5 Schütz K, Pallenberg ST, Kontsendorn J, *et al.* Spirometric and anthropometric

improvements in response to elexacaftor/tezacaftor/ivacaftor depending on age and lung

disease severity. *Front Pharmacol.* 2023;14:1171544.

6 Saluzzo F, Riberi L, Messore B, *et al.* CFTR Modulator Therapies: Potential Impact on

Airway Infections in Cystic Fibrosis. *Cells.* 2022;11:1243.

7 Lepissier A, Bonnel AS, Wizla N, *et al.* Moving the Dial on Airway Inflammation in

Response to Trikafta® in Adolescents with Cystic Fibrosis. *Am J Respir Crit Care Med.*

Published Online First: 4 January 2023. doi: 10.1164/rccm.202210-1938LE

8 Bass R, Brownell JN, Stallings VA. The Impact of Highly Effective CFTR Modulators on

Growth and Nutrition Status. *Nutrients.* 2021;13:2907.

9 Dreano E, Burgel PR, Hatton A, *et al.* Theratyping Cystic Fibrosis patients to guide

Elexacaftor-Tezacaftor-Ivacaftor out of label prescription. *European Respiratory Journal.*

Published Online First: 1 January 2023. doi: 10.1183/13993003.00110-2023

10 Fidler MC, Beusmans J, Panorchan P, *et al.* Correlation of sweat chloride and percent

predicted FEV1 in cystic fibrosis patients treated with ivacaftor. *Journal of Cystic Fibrosis.*

2017;16:41–4.

11 Ibrahim W, Carr L, Cordell R, *et al.* Breathomics for the Clinician: The use of volatile

organic compounds in respiratory diseases. *Thorax*. 2021;76:514–21.

12 Drabińska N, Flynn C, Ratcliffe N, *et al.* A literature survey of all volatiles from healthy

human breath and bodily fluids: the human volatilome. *J Breath Res*. 2021;15:034001. doi:

10.1088/1752-7163/abf1d0

13 Neerincx AH, Whiteson K, Phan JL, *et al.* Lumacaftor/ivacaftor changes the lung

microbiome and metabolome in cystic fibrosis patients. *ERJ Open Res*. 2021;7:00731–2020.

doi: 10.1183/23120541.00731-2020

14 Grassin-Delyle S, Roquencourt C, Moine P, *et al.* Metabolomics of exhaled breath in

critically ill COVID-19 patients: A pilot study. *EBioMedicine*. 2021;63:103154.

15 Roquencourt C, Salvator H, Bardin E, *et al.* Enhanced real-time mass spectrometry breath

analysis for the diagnosis of COVID-19. *ERJ Open Research*. Published Online First: 1

January 2023. doi: 10.1183/23120541.00206-2023

16 Li J, Zhang Y, Chen Q, *et al.* Development and validation of a screening model for lung

cancer using machine learning: A large-scale, multi-center study of biomarkers in breath.

Front Oncol. 2022;12:975563.

17 Bajtarevic A, Ager C, Pienz M, *et al.* Noninvasive detection of lung cancer by analysis of

exhaled breath. *BMC Cancer*. 2009;9:348.

18 Jung YJ, Seo HS, Kim JH, *et al.* Advanced Diagnostic Technology of Volatile Organic

Compounds Real Time analysis Analysis From Exhaled Breath of Gastric Cancer Patients

Using Proton-Transfer-Reaction Time-of-Flight Mass Spectrometry. *Front Oncol*.

2021;11:560591.

19 Stanojevic S, Vukovojac K, Sykes J, *et al.* Projecting the impact of delayed access to

elexacaftor/tezacaftor/ivacaftor for people with Cystic Fibrosis. *Journal of Cystic Fibrosis*.

2020;S1569199320308092.

20 Castellani C, Duff AJA, Bell SC, *et al.* ECFS best practice guidelines: the 2018 revision.

Journal of Cystic Fibrosis. 2018;17:153–78.

21 Roquencourt C, Grassin-Delyle S, Thévenot EA. ptairMS: real-time processing and analysis

of PTR-TOF-MS data for biomarker discovery in exhaled breath. *Bioinformatics*.

2022;38:1930–7.

22 Pang Z, Lu Y, Zhou G, *et al.* MetaboAnalyst 6.0: towards a unified platform for

metabolomics data processing, analysis and interpretation. *Nucleic Acids Research*.

2024;gkae253.

23 Barker M, Hengst M, Schmid J, *et al.* Volatile organic compounds in the exhaled breath of

young patients with cystic fibrosis. *Eur Respir J*. 2006;27:929–36. doi:

10.1183/09031936.06.00085105

24 Licht J-C, Seidl E, Slingers G, *et al.* Exhaled breath profiles to detect lung infection with

Staphylococcus aureus in children with cystic fibrosis. *Journal of Cystic Fibrosis*.

2023;22:888–93.

25 Weber R, Perkins N, Bruderer T, *et al.* Identification of Exhaled Metabolites in Children

with Cystic Fibrosis. *Metabolites*. 2022;12:980.

26 Kos R, Brinkman P, Neerincx AH, *et al.* Targeted exhaled breath analysis for detection of

Pseudomonas aeruginosa in cystic fibrosis patients. *Journal of Cystic Fibrosis*. 2022;21:e28–

34.

27 Gaisl T, Bregy L, Stebler N, *et al.* Real-time exhaled breath analysis in patients with cystic

fibrosis and controls. *J Breath Res*. 2018;12:036013.

28 Barucha A, Mauch RM, Duckstein F, *et al.* The potential of volatile organic compound

analysis for pathogen detection and disease monitoring in patients with cystic fibrosis.

Expert Rev Respir Med. Published Online First: 19 July 2022. doi:

10.1080/17476348.2022.2104249

29 Weber R, Haas N, Baghdasaryan A, *et al.* Volatile organic compound breath signatures of

children with cystic fibrosis by real-time SESI-HRMS. *ERJ Open Res*. 2020;6:00171–2019.

30 Woollam M, Siegel AP, Grocki P, *et al.* Preliminary method for profiling volatile organic

compounds in breath that correlate with pulmonary function and other clinical traits of

subjects diagnosed with cystic fibrosis: a pilot study. *J Breath Res*. 2022;16. doi:

10.1088/1752-7163/ac522f

31 Heijerman HGM, McKone EF, Downey DG, *et al.* Efficacy and safety of the elexacaftor

plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis

homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. *The*

Lancet. 2019;394:1940–8. doi: 10.1016/S0140-6736(19)32597-8

32 De Vincentis A, Vespasiani-Gentilucci U, Sabatini A, *et al.* Exhaled breath analysis in

hepatology: State-of-the-art and perspectives. *World J Gastroenterol*. 2019;25:4043–50.

33 Sutaria SR, Gori SS, Morris JD, *et al.* Lipid Peroxidation Produces a Diverse Mixture of

Saturated and Unsaturated Aldehydes in Exhaled Breath That Can Serve as Biomarkers of

Lung Cancer—A Review. *Metabolites*. 2022;12:561. doi: 10.3390/metabo12060561

34 Fei C-F, Guo S-M, Yin Y, *et al.* Exposure of mouse oocytes to N,N-dimethylformamide

impairs mitochondrial functions and reduces oocyte quality. *Environ Toxicol*. 2022;37:1563–

74.

35 Pan L, Chang P, Jin J, *et al.* Dimethylformamide Inhibits Fungal Growth and Aflatoxin B1

Biosynthesis in Aspergillus flavus by Down-Regulating Glucose Metabolism and Amino

Acid Biosynthesis. *Toxins (Basel)*. 2020;12:683.

36 Aridgides DS, Mellinger DL, Gwilt LL, *et al.* Comparative effects of CFTR modulators on

phagocytic, metabolic and inflammatory profiles of CF and nonCF macrophages. *Sci Rep*.

2023;13:11995. doi: 10.1038/s41598-023-38300-9

37 Blake RS, Monks PS, Ellis AM. Proton-transfer reaction mass spectrometry. *Chem Rev.*

2009;109:861–96.

38 Monteiro RRC, da Silva SSO, Cavalcante CL, *et al.* Biosynthesis of alkanes/alkenes from

fatty acids or derivatives (triacylglycerols or fatty aldehydes). *Biotechnology Advances.*

2022;61:108045.

39 Solomon GM, Fu L, Rowe SM, *et al.* The therapeutic potential of CFTR modulators for

COPD and other airway diseases. *Curr Opin Pharmacol.* 2017;34:132–9.

40 Rowe SM, Jones I, Dransfield MT, *et al.* Efficacy and Safety of the CFTR

Potentiator Icenticaftor (QBW251) in COPD: Results from a Phase 2 Randomized Trial. *Int

J Chron Obstruct Pulmon Dis*. 2020;15:2399–409.

41 Patel SD, Bono TR, Rowe SM, *et al.* CFTR targeted therapies: recent advances in cystic

fibrosis and possibilities in other diseases of the airways. *Eur Respir Rev*. 2020;29:190068.

42 Kuo T-C, Tan C-E, Wang S-Y, *et al.* Human Breathomics Database. *Database.*

2020;2020:baz139.

Table 1. Cohort characteristics and clinical readouts during the study.

Patient		01	02	03	04	05	06	07	08	09	10
Sex		F	M	M	M	M	M	M	M	F	M
Age range (y)		26-30	41-45	36-40	31-35	51-55	31-35	21-25	46-50	21-25	66-70
Genotype		F508del/ S1255P	F508del/ F508del	F508del/ F508del	F508del/ S945L	S945L(exon15) / I601F	3120G>A/ 3120G>A	N1303K/ N1303K	F508del/ E92K	F508del/ I148T	F508del/ 3849+10kbC>T
CFTR modulator treatment at V1		Ivacaftor	-	-	-	Ivacaftor	-	-	-	-	-
Therapy access		Eligible	Eligible	Eligible	Eligible	Off-label	Off-label	Off-label	Eligible	Eligible	Eligible
Sweat chloride (mmol/L)	V1	15	Failed	92	100	24.5	106	96	92.5	100	64
	V2	<10	ND	17	60	28.5	124	93	38	51.5	32.5
	V3	ND	ND	ND	58.5	<10	100.5	108	21.5	52	44
ppFEV1 (%)	V1	35	54	120	80	24	30	18	67	87	76
	V2	38	66	129	91	25	28	20	74	96	78
	V3	43	80	137	94	25	28	21	77	96	87
ppFVC (%)	V1	64	61	125	89	63	48	55	88	99	80
	V2	68	94	128	99	51	46	61	91	103	81
	V3	71	103	124	100	52	46	72	94	105	91
Clinical improvement at V3			Cough Dyspnea +3kg	Cough Sputum	Cough Sputum +5kg	Fatigue Sputum +1kg		Dyspnea Sputum +1kg	Cough Dyspnea Sputum	Cough Dyspnea Sputum	Cough Dyspnea +2kg
Response to ETI		Inconclusive	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes
ETI interruption		at one month	No	No	No	No	at two months	No	No	No	No

V1: baseline; V2: week 1; V3: month 1 of ETI treatment. ppFEV$_1$: percent predicted in forced expiratory volume in 1 second; ppFVC: percent predicted in forced vital capacity; ND = Not done.

Table 2. VOCs significantly modified upon ETI treatment and/or correlated with variations in clinical readouts.

m/z	Longitudinal p-value	Longitudinal slope%	ppFEV1 (V2-V1)	ppFEV1 (V3-V1)	ppFVC (V2-V1)	ppFVC (V3-V1)	Sweat chloride (V2-V1)	Sweat chloride (V3-V1)	Ion formula	Tentative annotations[#]
	All responders (n=8)		ppFEV1		ppFVC		Sweat chloride			
41.04	0.002**	-0.13							$[C_3H_4+H]^+$	Propadiene, propyne
41.05	0.017*	-0.23								Unknown 1
43.02	0.014*	-0.21	-0.75*	-0.39	-0.79*	-0.78**	0.67	-0.21		Unknown 2
45.00	0.021*	+0.06							$[CO_2+H]^+$	**Carbon dioxide**
55.04	0.002**	-0.1								Unknown 3
56.06			-0.54	-0.46	-0.83**	-0.59	-0.13	-0.53		Unknown 4
57.03	0.030*	-0.18							$[C_3H_4O+H]^+$	Propenal
57.07	0.045*	+0.11							$[C_4H_8+H]^+$	**Butene**
58.07			0.72*	0.58	0.46	0.42	-0.72*	0.07		Unknown 5
61.03	0.021*	-0.21	-0.74*	-0.27	-0.78*	-0.71*	0.66	-0.30	$[C_2H_4O_2+H]^+$	**Acetic acid**
61.05	0.008**	-0.18	-0.68*	-0.17	-0.69*	-0.56	0.59	-0.03		Unknown 6
63.04	0.004**	-0.14								Unknown 7
67.07			0.53	0.53	0.74*	0.67*	-0.18	0.76		Unknown 8
69.07	0.019*	-0.12							$[C_5H_8+H]^+$	**Pentadiene**
71.05			-0.56	-0.58	-0.89**	-0.89***	0.70	-0.42	$[C_4H_6O+H]^+$	**Butenal**
71.09	0.037*	-0.17	-0.47	-0.60	-0.84**	-0.86**	0.22	-0.01	$[C_5H_{10}+H]^+$	**Methylbutene**
71.11			0.81**	0.66*	0.66	0.40	-0.79*	-0.70		Unknown 9
73.02			0.39	0.43	0.72*	0.03	-0.02	-0.82	$[C_3H_4O_2+H]^+$	Oxopropanal, propanedial
73.06			-0.51	-0.70	-0.87**	-0.84**	0.57	0.52	$[C_4H_8O+H]^+$	**Butanone**
73.09			-0.52	-0.73	-0.86**	-0.78**	0.4	0.82		Unknown 10
74.06	0.005**	-0.17	-0.43	-0.56	-0.68*	-0.80**	0.45	-0.37	$[C_3H_7NO+H]^+$	**Dimethylformamide**
75.07	0.048*	-0.17								Unknown 11
79.04	0.025*	-0.21	-0.74*	-0.29	-0.83**	-0.69*	0.69	-0.27		Unknown 12
79.05			-0.61	0.33	-0.69*	-0.02	0.20	-0.17	$[C_6H_6+H]^+$	**Benzene**
79.08	0.019*	-0.22								Unknown 13
80.05			-0.53	-0.50	-0.86**	-0.31	0.36	0.29	$[C_5H_5N+H]^+$	**Pyridine**
81.07			0.62	-0.50	0.33	-0.20	-0.73*	0.29	$[C_6H_8+H]^+$	**Methylpentenyne, methylcyclopentadiene,**

m/z	p-value	slope							Ion	Identification
										cyclohexadiene
85.10	0.041*	+0.06	0.72*	0.76*	0.40	0.53	-0.59	-0.49	$[C_6H_{12}+H]^+$	**Methylpentene, hexene**
85.13			0.71*	0.64*	0.59	0.73	-0.43	0.20		Unknown 14
88.08			0.66	0.77	0.99***	0.3	-0.45	-0.41	$[C_4H_9NO+H]^+$	2-methylpropanamide
89.04	0.047*	-0.25	-0.58	-0.34	-0.78*	-0.76*	0.42	-0.04	$[C_4H_8S+H]^+$	Methylsulfanylpropene
89.06	0.048*	-0.28	-0.55	-0.59	-0.89**	-0.89***	0.62	-0.32	$[C_4H_8O_2+H]^+$	**Methylpropanoic acid, ethyl acetate**
89.09			-0.55	-0.63	-0.88**	-0.88***	0.50	-0.04	$[C_5H_{12}O+H]^+$	**Pentanol**
99.12			0.68*	0.67*	0.43	0.59	-0.51	0.17	$[C_7H_{14}+H]^+$	**Dimethylpentene, heptene**
107.08			-0.56	-0.49	-0.85**	-0.80**	0.44	0.13	$[C_8H_{10}+H]^+$	**Ethylbenzene**
113.06			-0.74*	-0.17	-0.41	-0.30	0.70	-0.28		Unknown 15
113.13			0.84**	0.41	0.62	0.40	-0.47	0.06	$[C_8H_{16}+H]^+$	**Dimethylhexene, methylheptene, octene, methylmethylidenehexane, methylideneheptane**
119.09	0.012*	-0.14							$[C_9H_{10}+H]^+$	**Propenylbenzene, ethenylmethylbenzene**
127.15			0.74*	0.36	0.41	0.23	-0.42	-0.14	$[C_9H_{18}+H]^+$	**Nonene**
135.11			0.66	0.82	0.85**	0.57	-0.45	-0.28	$[C_6H_{14}O_3+H]^+$	Ethoxyethoxyethanol
137.13			0.60	-0.68	0.28	-0.46	-0.72*	0.24	$[C_{10}H_{16}+H]^+$	**Dimethyloctatriene**
139.08	0.047*	-0.14							$[C_8H_{10}O_2+H]^+$	**2-phenoxyethanol**
139.15			0.60	0.54	0.85**	0.49	-0.68	-0.61	$[C_{10}H_{18}+H]^+$	**Dimethyloctadiene,**
177.16			-0.49	-0.03	-0.69*	0.06	0.30	0.38	$[C_{13}H_{20}+H]^+$	**Heptylbenzene**

p-value obtained with a mixed model built with patients responding to ETI; longitudinal slope indicates the direction of the evolution;

correlations are calculated between variations in VOC concentrations (between V1 and V2 or between V1 and V3) and variations in clinical

readouts; #tentative chemical identification is based on exact mass match with the human breathomics database [42], likelihood of compound

ionisation by proton transfer reaction [37], and detection by TD-GCxGC-MS in the breath of healthy adults and/or of children with CF (VOCs in

bold); *p-value<0.05; **p-value<0.01; ***p-value<0.001.

FIGURE LEGENDS

Figure 1. PLS-DA showing the distribution of breath samples collected from responder patients at baseline in red (V1), after one week in green (V2), and one month of ETI treatment in blue (V3); dashed lines link samples taken from the same patient; * indicates the patient with chronic hepatopathy; shaded areas represent confidence intervals (95%); $R2=0.997$; $Q2=0.187$.

Figure 2. Longitudinal evolution from baseline (V1), one week (V2), and one month of treatment (V3), of four VOCs significantly modified in the breath of responder patients upon ETI initiation, compared to the level measured in healthy volunteers (normalised intensities) **(A)**. Corresponding graphs illustrating correlations (Pearson) between variations in VOCs and variations in ppFVC or ppFEV1 between V1 and V2, and between V1 and V3, are shown **(B)**. *p-value<0.05; **p-value<0.01; ***p-value<0.001; ****p-value<0.0001; ns = not significant.

SUPPLEMENTARY INFORMATION

Table S1. List of concomitant treatments and bronchial exacerbations during the study.

Patients	Chronic anti-infectious treatments	Acute respiratory infections and other antibiotics received during the study
01	Azithomycin, oral Tobramycine and aztreonam, inhaled	COVID-19, treatment with amoxicillin and ciprofloxacin
02	Azithromycin, oral	
03	None	None
04	None	None
05	Azithromycin, oral Pristinamycin and amoxicillin-calvulanic acid, oral	
06	Azithromycin, oral	
07	Azithromycin, oral Tobramycin and colimycin, inhaled	COVID-19, treatment with ceftazidim and docycyline
08	Azithromycin, oral	
09	None	None
10	Azithromycin, oral	Viral syndrom

Figure S1. Principal component analysis (PCA) representing the breath samples collected from each patient at baseline (V1), after one week (V2) and one month of ETI treatment (V3).

Figure S2. Heatmap of the log-transformed concentrations (ppb) of the 108 VOCs detected in the breath of the 10 patients at V1/V2/V3.

Figure S3. Longitudinal evolution from baseline (V1), one week (V2), and one month of treatment (V3), of additional VOCs, significantly modified in the breath of responder patients upon ETI initiation, compared to the level measured in healthy volunteers (normalised intensities). *p-value<0.05; **p-value<0.01; ***p-value<0.001; ****p-value<0.0001; ns = not significant.

Figure 1

Scores Plot PLS-DA

Figure 2

A. Longitudinal evolution

B. Correlation between VOCs and lung function

ETI response
- No
- Yes
- unconclusive

Figure S1

Figure S2

Figure S3